Literature DB >> 20332664

Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.

Ji Kon Ryu1, Seung-Mo Hong, Collins A Karikari, Ralph H Hruban, Michael G Goggins, Anirban Maitra.   

Abstract

BACKGROUND/AIMS: Pancreatic intraepithelial neoplasia (PanIN) is the most common noninvasive precursor to invasive pancreatic adenocarcinoma. Misexpression of microRNAs (miRNAs) is commonly encountered in invasive neoplasia; however, miRNA abnormalities in PanIN lesions have not been documented.
METHODS: Three candidate miRNAs (miR-21, miR-155, and miR-221) previously reported as overexpressed in pancreatic cancers were assessed in 31 microdissected PanINs (14 PanIN-1, 9 PanIN-2, 8 PanIN-3) using quantitative reverse transcription PCR (qRT-PCR). Subsequently, miR-155 was evaluated by locked nucleic acid in situ hybridization (LNA-ISH) in PanIN tissue microarrays.
RESULTS: Relative to microdissected non-neoplastic ductal epithelium, significant overexpression of miR-155 was observed in both PanIN-2 (2.6-fold, p = 0.02) and in PanIN-3 (7.4-fold, p = 0.014), while borderline significant overexpression of miR-21 (2.5-fold, p = 0.049) was observed in PanIN-3 only. In contrast, no significant differences in miR-221 levels were observed between ductal epithelium and PanIN lesions by qRT-PCR. LNA-ISH confirmed the aberrant expression of miR-155 in PanIN-2 (9 of 20, 45%) and in PanIN-3 (8 of 13, 62%), respectively, when compared with normal ductal epithelium (0 of 10) (p < 0.01).
CONCLUSIONS: Abnormalities of miRNA expression are observed in the multistep progression of pancreatic cancer, with miR-155 aberrations demonstrable at the stage of PanIN-2, and miR-21 abnormalities at the stage of PanIN-3 lesions. and IAP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332664      PMCID: PMC2865485          DOI: 10.1159/000231984

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  55 in total

1.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

2.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

3.  Widespread microRNA repression by Myc contributes to tumorigenesis.

Authors:  Tsung-Cheng Chang; Duonan Yu; Yun-Sil Lee; Erik A Wentzel; Dan E Arking; Kristin M West; Chi V Dang; Andrei Thomas-Tikhonenko; Joshua T Mendell
Journal:  Nat Genet       Date:  2007-12-09       Impact factor: 38.330

4.  MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA.

Authors:  William Kong; Hua Yang; Lili He; Jian-jun Zhao; Domenico Coppola; William S Dalton; Jin Q Cheng
Journal:  Mol Cell Biol       Date:  2008-09-15       Impact factor: 4.272

5.  The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2.

Authors:  Manav Korpal; Esther S Lee; Guohong Hu; Yibin Kang
Journal:  J Biol Chem       Date:  2008-04-14       Impact factor: 5.157

6.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.

Authors:  Philip A Gregory; Andrew G Bert; Emily L Paterson; Simon C Barry; Anna Tsykin; Gelareh Farshid; Mathew A Vadas; Yeesim Khew-Goodall; Gregory J Goodall
Journal:  Nat Cell Biol       Date:  2008-03-30       Impact factor: 28.824

7.  MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene.

Authors:  Z Lu; M Liu; V Stribinskis; C M Klinge; K S Ramos; N H Colburn; Y Li
Journal:  Oncogene       Date:  2008-03-31       Impact factor: 9.867

8.  MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival.

Authors:  Mary Dillhoff; James Liu; Wendy Frankel; Carlo Croce; Mark Bloomston
Journal:  J Gastrointest Surg       Date:  2008-07-19       Impact factor: 3.452

Review 9.  Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts.

Authors:  Georg Feldmann; Anirban Maitra
Journal:  J Mol Diagn       Date:  2008-02-07       Impact factor: 5.568

10.  Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth.

Authors:  Xiaohong Wang; Shuang Tang; Shu-Yun Le; Robert Lu; Janet S Rader; Craig Meyers; Zhi-Ming Zheng
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

View more
  63 in total

Review 1.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

2.  miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts.

Authors:  Hanno Matthaei; Dennis Wylie; Maura B Lloyd; Marco Dal Molin; Jon Kemppainen; Skye C Mayo; Christopher L Wolfgang; Richard D Schulick; Laura Langfield; Bernard F Andruss; Alex T Adai; Ralph H Hruban; Anna E Szafranska-Schwarzbach; Anirban Maitra
Journal:  Clin Cancer Res       Date:  2012-06-21       Impact factor: 12.531

Review 3.  Tracking miRNAs' footprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy.

Authors:  Nazila Nouraee; Seyed Javad Mowla; George A Calin
Journal:  Genes Chromosomes Cancer       Date:  2015-03-31       Impact factor: 5.006

4.  Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma.

Authors:  Ji Kon Ryu; Hanno Matthaei; Marco Dal Molin; Seung-Mo Hong; Marcia I Canto; Richard D Schulick; Christopher Wolfgang; Michael G Goggins; Ralph H Hruban; Leslie Cope; Anirban Maitra
Journal:  Pancreatology       Date:  2011-07-12       Impact factor: 3.996

Review 5.  Targeting microRNAs in pancreatic cancer: microplayers in the big game.

Authors:  Sheema Khan; Deepak Kumar; Meena Jaggi; Subhash C Chauhan
Journal:  Cancer Res       Date:  2013-11-07       Impact factor: 12.701

Review 6.  MicroRNAs in pancreatic malignancy: progress and promises.

Authors:  Sanjeev K Srivastava; Sumit Arora; Seema Singh; Arun Bhardwaj; Courey Averett; Ajay P Singh
Journal:  Cancer Lett       Date:  2014-02-20       Impact factor: 8.679

Review 7.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

8.  Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology.

Authors:  Lester J Layfield; Hormoz Ehya; Armando C Filie; Ralph H Hruban; Nirag Jhala; Loren Joseph; Philippe Vielh; Martha B Pitman
Journal:  Diagn Cytopathol       Date:  2014-04       Impact factor: 1.582

9.  The efficacy evaluation of cryosurgery in pancreatic cancer patients with the expression of CD44v6, integrin-β1, CA199, and CEA.

Authors:  Gang Zhou; David Chiu; Dajiang Qin; Lizhi Niu; Jinlei Cai; Lihua He; Wenhao Huang; Kecheng Xu
Journal:  Mol Biotechnol       Date:  2012-09       Impact factor: 2.695

10.  Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy.

Authors:  Mohammad Aslam Khan; Haseeb Zubair; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.